SIEMENS HEALTHINEERS AGSS

SIEMENS HEALTHINEERS AG

52.300EURD
−1.100−2.06%
At close at Mar 6, 21:02 GMT
EUR
No trades
See on Supercharts

SHL fundamentals

Key facts

Market capitalization‪59.11 B‬EUR
Founded2017
Employees (FY)‪72 K‬
CEOBernhard Montag
About

Siemens Healthineers AG is a holding company that provides healthcare equipment, solutions, and services globally. It operates through the following business segments: Imaging, Diagnotics, Varian and Advanced Therapies. The Imaging segment provides imaging products, services, and solutions as well as digital offerings. The Diagnostics segment provides a broad array of testing applications, in the areas of laboratory, point of care and molecular diagnostics. The Varian segment provides innovative, multi-modality cancer care technologies based on integrated, advanced imaging, along with solutions and services to oncology departments in hospitals and clinics globally. The Advanced Therapies segment consist of integrated products, services and solutions across multiple clinical fields used in the treatment of diseases. Siemens Healthineers was founded on December 1, 2017 and is headquartered in Forchheim, Germany.

Ownership
‪‪1.12 B‬‬
Closely held shares
‪‪855.54 M‬‬ (76.44%)
Free Float shares
‪‪263.73 M‬‬ (23.56%)
Closely held shares
‪‪855.54 M‬‬ (76.44%)
Free Float shares
‪‪263.73 M‬‬ (23.56%)
Capital structure
Market cap
‪‪59.11 B‬‬
Debt
‪‪16.21 B‬‬
Minority interest
‪‪49.00 M‬‬
Cash & equivalents
‪‪2.68 B‬‬
Enterprise value
‪‪72.69 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪59.11 B‬‬
Price to earning ratio (P/E)
30.90x
Price to sales ratio (P/S)
2.68x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
30.90x
Price to sales ratio (P/S)
2.68x
Valuation ratios
‪0.00‬
‪0.80‬
‪1.60‬
‪2.40‬
‪3.20‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪10.00‬
‪20.00‬
‪30.00‬
‪40.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪7.5%‬
‪8.1%‬
‪8.7%‬
‪9.3%‬
‪9.9%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪1.60 B‬‬
‪‪3.20 B‬‬
‪‪4.80 B‬‬
‪‪6.40 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪1.60 B‬‬
‪‪3.20 B‬‬
‪‪4.80 B‬‬
‪‪6.40 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪1.60 B‬‬
‪‪3.20 B‬‬
‪‪4.80 B‬‬
‪‪6.40 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Imaging
Diagnostics
Varian
Advanced Therapies
Reconciliation to Consolidated Financial Statements
By country
Period: 2024
United States
Europe, Commonwealth of Independent States, Africa, Middle East
Asia Pacific, Japan
China
Germany
Americas

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪0.00‬
‪‪1.60 B‬‬
‪‪3.20 B‬‬
‪‪4.80 B‬‬
‪‪6.40 B‬‬
Actual
Estimate
Earnings
Next:May 7, 2025
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪0.00‬
‪0.17‬
‪0.34‬
‪0.51‬
‪0.68‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
54.70%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
1.79%
Last payment
0.95
Last ex-date
Feb 19, 2025
Dividend history
‪1.50%‬
‪1.67%‬
‪1.84%‬
‪2.01%‬
‪2.18%‬
2020
2021
2022
2023
2024
‪0.00‬
‪0.25‬
‪0.50‬
‪0.75‬
‪1.00‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪4.50 B‬‬
‪‪9.00 B‬‬
‪‪13.50 B‬‬
‪‪18.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪8.00 B‬‬
‪‪16.00 B‬‬
‪‪24.00 B‬‬
‪‪32.00 B‬‬
Assets
Liabilities